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Two analogs of rat atria1 natriuretic factor, rANF, _28-N& and [Mpr7,Alaz0,D-ArgZ’]rANF, _27-NH2, were prepared by 
the solid-phase method. These peptides had 2-fold and 7-fold less affinity, respectively, than rANF, _28 in binding to mem- 
branes prepared from cultured aortic smooth muscle cells, and both peptides were S-fold less potent than rANF, -28 in 
relaxing serotonin-contracted rabbit aortic rings. rANF, +,-NH2 was rapidly degraded by rat kidney homogenates but 
[Mpr7,Alazo,D-A&‘]rANF, _,-NHZ had enhanced stability against rat kidney homogenate degradation. However, this 
in vitro stability did not translate into an extended uration of action in vivo. 
Atria1 natriuretic factor; Proteolytic degradation 
1. INTRODUCTION 
The discovery of a family of potent vasodilatory, 
natriuretic, and diuretic peptides (collectively re- 
ferred to as atria1 natriuretic factors) has led to 
considerable research activity (for reviews see re- 
ferences [l-5]). As with other key regulatory pep- 
tide hormones, the intrinsic biological activity of 
atria1 natriuretic factor (ANF) is short lived. In the 
case of ANF, this presumably allows a precise and 
proper balance of the contribution of ANF to the 
maintenance of extracellular fluid volume. We 
wished to exploit the desirable biological activities 
of ANF and prepare analogs that showed a pro- 
longation of biological action. Central to this ap- 
proach is the ability to modify the parent structure 
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profile against enzymatic degradation while main- 
taining biological activity. 
The rational design of metabolically stable ana- 
logs requires an understanding of proteolytic inac- 
tivation in vivo. However, the in vivo enzymatic 
degradation of peptide hormones is a complex pro- 
cess. Kidney homogenate preparations are often 
used as in vitro models of peptide degradation [6]. 
We determined the products of rat (r)ANFT- us- 
NH2 degradation by a soluble rat kidney homo- 
genate preparation [7]. The initial degradation 
products are the C-terminal hydrolyzed com- 
pounds rANF7 _ 27, rANF7 _ 26, and rANF7 - 25. We 
proposed that the initial proteolysis of rANF 
rANF7 -2s-NH2 (by rat kidney homogenate) in- 
volved a trypsin-like cleavage of the Arg27-Tyr28 
amide linkage. 
This report describes the synthesis and biological 
profile of rANF7 _ 2s-NH2, and [Mpr7,AlaZo,D- 
Arg27]rANF7 - 27-NH2 (which was designed to 
resist proteolysis). 
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2. MATERIALS AND METHODS Time (min) 
2.1. Peptides 
Peptides were assembled by the stepwise solid-phase method 
[8]. Protected peptides were prepared beginning with 0.5 mmol 
resin by standard synthetic techniques using an automated pep- 
tide synthesizer. N”-tert-Butyloxycarbonyl (Boc) protected 
amino acids and p-methyl-benzhydrylamine resin (1.1 
mequiv./g) were purchased from Peptides International (Louis- 
ville, KY). The cycle used for incorporation of each Boc amino 
acid is shown in scheme 1. After completion of the stepwise 
assembly of the required sequence the N-terminal Boc group 
was removed using 60% TFA, 1.5% anisole in CHzCl2 and the 
resin dried in vacua. Peptides were deprotected and removed 
from the resin with anhydrous liquid HF (10 ml/g resin) con- 
taining 10% anisole for 45 min at 0°C. After removal of the HF 
in vacua, the peptides were extracted with 30% acetic acid, 
rinsed with ethyl ether, and lyophilized. Purification of peptides 
utilized gel filtration on Sephadex G-25F, SP-Sephadex cation- 
exchange chromatography, and preparative HPLC. Homo- 
geneity was assessed by analytical reversed-phase HPLC (two 
solvent systems), amino acid analysis, and FAB-MS. 
60% TFA, 1.5% anisole in CHzCl2 2 
60% TFA, 1.5% anisole in CHzClz 17 
4 x CHzCl2 0.5 
2 x 25% DIEA in DMF 1 
2xDMF 1 
1st couplinga in DMF 22 
2xDMF 1 
25% DIEA in DMF 1 
3xDMF 1 
2nd couplinga in CHzCIz 22 
2xDMF 1 
25% DIEA in DMF 1 
3xDMF 1 
Capping (25% acetic anhydride in CHzC12) 10 
4 x CHzC12 1 
a 2-fold excess of preformed symmetrical anhydride (Arg, Asn, 
and Gln 4-fold excess of preformed I-hydroxybenzotriazole 
esters) 
Scheme 1. 
2.1.1. (S-pMeBzl)3-mercaptopropionic acid 
To a cooled solution (0°C) of 3-mercaptopropionic acid (5 g, 
47 mmol) in THF (40 ml) under Nz, NaH (3.7 g, 61.1% oil 
dispersion, 94 mmol, portionwise over 5 min), and p-methyl- 
benzyl bromide (8.7 g, 47 mmol, dropwise over 20 min) were 
added. The suspension was stirred overnight at room tempera- 
ture, DMF (60 ml) was added, stirring continued for 0.5 h, and 
then 10% NaHC03 (50 ml) was added. The solvents were re- 
moved under reduced pressure, the residue suspended in Hz0 
(500 ml), and washed with EtOAc (3 x 100 ml). The aqueous 
phase was acidified to pH 3 with 5 N HCI, extracted with EtOAc 
(3 x 100 ml), the combined EtOAc washings were extracted with 
saturated NaCl (3x50 ml), dried (NazSOd), and the solvent 
removed under reduced pressure to give 8.6 g of a gray oil. A 
portion of the oil (7.1 g) was purified by preparative liquid 
chromatography (Waters Prep 500) using EtOAc/hexanes 
(3 : 7). The desired fractions were pooled, the solvent removed 
under reduced pressure, and the residue recrystallized from 
warm EtOAc/hexanes (20 ml: 100 ml) to give the desired 
product (5.97 g, 60%, m.p. 74-76°C [9]). 
2.1.2. H-C~s-Phe-Gly-GIy-Arg-Ile-Asp-Arg-Ile-G1y-AIa-Gln- 
Ser-Gly-Leu-Gly-C$s-Asn-Ser-Phe-Arg-Tyr-NH2 
(rANF7 _ zs-NHz). 
Synthesis was initiated by charging the reaction vessel with p- 
1 Hz0 and the pH adjusted to 8.3 with aqueous ammonia. A 
solution of 0.01 M K3Fe(CN)6 (27 ml) was added over 10 min 
and stirring continued for 30 min. The pH was adjusted to 5.0 
with AcOH and excess ferro- and ferricyanide removed by the 
addition of 10 ml BioRad AG3-X4A(Cl- form) anion-exchange 
resin. After stirring for 30 min the resin was removed by filtra- 
tion and the solution concentrated in vacua (30°C) to 10 ml. The 
cyclized peptide was desalted on a Sephadex G-25F column 
(2.5x85 cm) using 30% AcOH. Appropriate fractions were 
pooled and freeze dried (225 mg). The peptide powder was 
dissolved in 10% AcOH/20 mM NaOAc and applied to an SP- 
Sephadex cation-exchange column (1 x 45 cm). The peptide was 
eluted with a linear salt (NaCI) gradient from 0 to 1.5 M in 300 
ml of the same buffer. The major peak was pooled, lyophilized, 
desalted by gel filtration on a Sephadex G-25F column (2.5 x 85 
cm), and appropriate fractions pooled and lyophilized to give 99 
mg material. This material was purified to homogeneity by 
preparative gradient HPLC (30% B-40% B over 25 min, flow 
rate 9 ml/min, Vydac 218TPl022 [2.2x 25 cm], A= 0.1% TFA, 
B = 0.1% TFA, 60% MeCN). The lyophilizate from 6 injections 
(about 15 mg each) yielded 24 pmol of the title compound 
(overall yield 9.6% based on initial resin substitution). Amino 
acid analysis: Asp 1.77 (2), Glu 1 .Ol (I), Ser 1.84 (2), Gly 5.08 
(5),Alal.05(l),Arg2.89(3),Tyr0.90(l),Ilel.80(2),Leu0.99 
(1), Phe 1.89 (2). FAB mass spectrum: [M+H]+ talc. 2373; 
found 2373. 
methylbenzhydrylamine r sin (0.45 g, 0.50 mmol). The pro- 
tected peptide resin corresponding to the title compound was 
obtained after stepwise coupling of the appropriate N”-Boc- 
amino acids. Trifunctional amino acids were protected as 
follows: N”-Boc-Cys(pMeBzl)-OH; N”-Boc-Ser(Bzl)-OH; N”- 
Boc-Cys(pMeBzl)-OH; N”-Boc-Arg(Tos)-OH; N”-Boc-Asp- 
(Chx)-OH. A portion of the protected peptide resin (1.2 g) was 
treated with liquid HF/anisole for 45 min at 0°C. After 
evaporation of HF, the product was extracted with 100 ml 30% 
AcOH, washed with Et20 (3 x 25 ml), and extracted with an ad- 
ditional 30% AcOH (3 x 20 ml). The AcOH extracts were com- 
bined and freeze dried. The peptide powder was dissolved in 1.8 
2.1.3. Mrpr-Phe-Gly-Gly-Arg-IIe-Asp-Arg-Ile-Gly-Ala-Gln- 
Ser-Ala-Leu-Gly-Cy&-Asn-Ser-Phe-D-Arg-NH2 
([Mpr’,Ala”,D-Arg2’]rANF7 - z7-NH2) 
Amino acid analysis: Asp 1.58 (2), Glu 0.89 (1). Ser 1.79 (2), 
Gly4.09(4),Ala2.06(2),Arg2.90(3),Ile1.97(2),Leu0.98(1), 
Phe 2.06 (2). FAB mass spectrum: [M + HI+ talc. 2209; found 
2.1.4. H-Ser-Leu-Arg-Arg-Ser-Ser-Cfrs-Phe-Gly-Gly-Arg-Ile- 
t Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser- 
Phe-Arg-Tyr-OH (rANF, _ 2s) 
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Amino acid analysis: Asp 1.22 (2), Glu 0.95 (1). Ser 4.73 (5), 
Gly 5.16 (5), Ala 0.93 (l), Arg 4.88 (5), Tyr 0.99 (l), Ile 2.04 (2), 
Leu 2.09 (2), Phe 2.10 (2). FAB mass spectrum: [M + H]+ talc. 
3060; found 3062 * 2. 
2.2. Enzymatic degradation 
Rat kidneys were excised, minced and homogenized in ice- 
cold 50 mM sodium phosphate buffered saline (10 ml/kidney) at 
pH 7.4. The homogenate was centrifuged for 20 min at 
48OOOxg at 4°C. The supernatant (100 ~1) was added to 10 
nmol peptide (freeze dried powder), and incubated at 37°C for 
various times. Enzymatic activity was destroyed by dipping the 
sample tubes into boiling water for 2 min. The tubes were cen- 
trifuged at 4000 rpm for 2 min. Supernatants (50 ~1) were then 
subjected to reverse-phase HPLC [column: Vydac 218TP54 (25 
cm x 4.6 mm i.d.), with a Macrosphere 300 A C-4, 7 pm, guard 
column (1 cm x 4.6 mm i.d.)]. Mobile phase: A = HzO/CH&N 
(85 : 15) containing 0.01 M ammonium acetate, and B = H20/ 
CH$N (50: 50) containing 0.01 M ammonium acetate. A linear 
gradient was run from 0% B to 60010 B over 30 min at a flow rate 
of 1.5 ml/min. 
3. RESULTS 
The compounds were evaluated in several dif- 
ferent assays, both in vitro and in vivo, and the 
results are presented in table 1. In an assay for 
Table 1 
competition of the binding of 12?-rANF5 _z8 to 
cultured SHR vascular smooth muscle membranes 
rANF7 - 2s-NH2 had 2-fold less affinity and [Mpr7, 
Ala”,D-Argz7]rANF7 _ 27-NHz had 7-fold less af- 
finity than rANFl _ 2s. In an in vitro vasodilatory 
assay employing serotonin-contracted rabbit aortic 
rings, both rANF analogs were 5fold less potent 
than rANFl _ 2s in inducing relaxation. In vivo in 
anesthetized normotensive rats, rANF7 _ 28-NH2 
was slightly more potent in producing natriuresis/ 
diuresis than rANFl - 2s while [Mpr7,Ala2’,D- 
Arg27]- rANF7 - 27-NH2 was essentially equipotent 
with rANFl - 28. Table 1 lists the bolus dose 
(nmol/kg, i.v.) required to elicit a 1 ml/10 min 
diuresis (EDI) and UN,V of 200 ,umol/lO min 
(EDZOO). The ED1 and EDZOO values reflect half- 
maximal responses. 
The half lives (f4 of the analogs towards pro- 
teolysis by the rat kidney preparation are shown in 
table 1. The amino and carboxyl modified com- 
pound [Mpr7,Ala20,D-Arg27]rANF7 - z7-NH2 has a 
27-fold enhanced stability to the proteolytic en- 
zymes present in this tissue preparation. 
Compound Binding affinitya Vasodilatory Diuresis’ Natriuresis’ Kidney 
(I&o + SE, PM) activityb (ED1 t SE, (ED200 + SE, Homogenated 
(ED30 f SE, nM) nmol/kg) nmol/kg) (t1/2, min) 
rANFl _ 2s 
rANF7 _ 2s-NH2 
[Mpr’ Ala2’ D-Arg2’] , f 
rANF7 _ ~YNHz 
2.5 + 1.0 6.5 + 2.3 1.80 k 0.22 1.72 + 0.19 1.5 
5.0 * 2.0 31.5 * 2.4 1.00 + 0.09 1.18 c 0.12 3.1 
18.0 + 6.0 32.4 t 4.9 1.53 t 0.09 1.59 * 0.11 40.8 
a Competition for the binding of 0.1 nM ‘251-rANFs _2s was determined in crude membranes from cultured aortic smooth muscle cells 
from SHR at 4°C in 50 mM Tris buffer (pH 7.4, 4”C, 90 min) containing 400 pg/ml bovine serum albumin, 40 #g/ml bacitracin, 
4rg/ml leupeptin, 4,ug/ml chymostatin, and 5 pM phenylmethylsulfonyl fluoride, ICSO, concentration producing 50% inhibition of 
maximum specific binding. N, 5-10 determinations 
b New Zealand white rabbits (3-5 kg) were killed by cervical dislocation. Aortic rings (2 mm) were mounted under 3 g tension in a 3 
ml chamber containing Burns Modified Tyrodes solution maintained at 37°C and aerated with 95% 02-5% COZ. Each ring was 
equilibrated for 60 min. Rings were contracted with serotonin (2OpM) and, once the contractile response stabilized, exposed to rANF 
in half-log increments beginning at lo- ” M. Relaxation was determined in six preparations and the linear part of the concentration- 
response curve was used to calculate the EDSO values. N= 6 
’ Natriuretic-diuretic assays were performed under Pentobarbital/Inactin@ anesthesia in male Sprague-Dawley rats (200-350 g). 
Catheters were placed in the left carotid artery, the right jugular vein and bladder. The animals were infused with 0.15 ml/min of 
saline. The protocol was begun when urine flow rate stabilized at 20-150~1/10 min. Urine was collected for three consecutive IO-min 
control periods and then rANF was administered intravenously as a 100 rl/lOO g body weight bolus. Urine samples were collected 
for an additional 30 min at 10 min intervals. Only one rANF analog was assayed in each rat. Initial 10 min-periods following rANF 
injection were compared. Relative activities were determined as the dose that produces 1.0 ml/10 min of urine (ED,) and 2OOymoYlO 
min sodium excretion (ED& using at least 3 data points (N= 4) from the linear portion of the dose-response curve. Sodium concen- 
trations were measured by an ion-selective lectrode (Orion) 
d The tl12 (metabolic half-life) values were determined graphically by plotting the log of the peak area A214 nm vs time assuming first 
order kinetics 
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4. DISCUSSION 
We set out to design ANF analogs that were 
stabilized against enzymatic inactivation at the 
amino- and carboxyl-terminal extensions. The se- 
quence of rANF is shown in fig.1. It consists of a 
17 amino acid disulfide linked cyclic structure 
flanked by amino- and carboxyl-terminal exocyclic 
extensions. Structure activity studies have shown 
the following key features: (i) the cyclic core 
(rANF7 - 23) possesses minimal biological activity 
[lo]; (ii) the entire N-terminal exocyclic tail (resi- 
dues l-6) is not required for full activity [l 11; (iii) 
Tyr2* may be deleted [l 11, and (iv) C-terminal car- 
boxamides have good activity [12]. 
Indeed, the C-terminal carboxamide rANF7 - 28- 
NH2 has a biological profile quite similar to the en- 
dogenous peptide (table 1). It is, however, rapidly 
degraded by rat kidney homogenates (table 1). 
The initial degradation of rANF7-2s-NH2 by 
soluble proteases of rat kidney homogenates 
resulted from cleavage of the Arg27-Tyr28 amide 
bond [7]. We reasoned that substitution of Arg27 
by its D isomer should prevent this hydrolysis. Ad- 
ditionally, in order to protect against aminopep- 
tidase mediated degradation we substituted Cys7 
with 3-mercaptopropionic acid (Mpr). Structure 
function studies with oxytocin have demonstrated 
the utility of replacing an N-terminal cysteine with 
Mpr [13]. This modification is also tolerated in 
ANF analogs [14-161. 
The amino- and carboxyl-terminal modified 
analog [Mpr7,Ala20,D-Arg27]-rANF7 - 27-NH2 
maintains very high affinity for 1251-rANFs - 28 bin- 
ding sites in aortic smooth muscle membranes. 
These low pM affinity binding sites for ANF have 
also been reported in rat renal glomerular mem- 
branes and in rabbit carotid artery smooth muscle 
cells [17-191. They may be receptors that are 
biologically silent or linked to as yet unknown 
functions of ANF. [Mpr7,Ala20,D-Arg27]- 
rANF7 - 27-NH2 also has vasodilatory and natriure- 
tic/diuretic activity comparable to the endogenous 
peptide (table 1). 
When assayed for stability against kidney 
homogenate degradation [Mpr7,Ala20,D-Arg27]- 
rANF7 _ z7-NH2 has greatly enhanced stability. 
Substitution with D-Arg at position 27 prolongs 
the in vitro half-life. Disappointingly, 
[Mpr7,Ala20,D-Arg27]rANF7 _ 27-NH2 does not 
show an increase in duration of biological activity 
when assayed in the anesthetized rat. Fig.2 shows 
that [Mpr7,Ala20,D-Arg27]rANF7 _ 27-NH2 has a 
time-response relationship that is essentially 
parallel to rANFi _ 28. The lack of in vivo duration 
could be due to rapid endopeptidase mediated 
Fig. 1. Structure of rANFl _ 28. 
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-10-o O-10 10-20 20-30 
Minutes 
m rANF,_, (2 nmole/kg. n=5) 
m rANF,_,, -NH, (2 nmole/kg. n=4) 
m [Mpr7.Ala~.D-Arg2’)~~~ 7_27-NH2 (2 nmole/kg. n=4) 
l p < 0.05 compared to preinjection value 
l *p < 0.01 compared to proinjection value 
Fig. 2. 
cleavages or excretion. The appropriateness of our 
kidney preparation may be questionable because 
there is no correlation between in vitro stability and 
in vivo duration. More likely, the lack of correla- 
tion is attributable to the complexity of the in vivo 
metabolism of ANF. 
Recently, several reports describing the metabo- 
lism of ANF have appeared. Endopeptidase 24.11 
and thermolysin appear to cleave ANF’s X-hydro- 
phobic linkages [20,21]. The initial cleavage site 
appears to be the Cys7-Phe’ linkage [21]. Condra et 
al. [22] have described the in vivo metabolism of 
12’I-ANF in rats and found that several other 
amides are susceptable to proteolysis. 
In conclusion, we have prepared a novel rANF 
analog that has enhanced stability towards pro- 
teolysis by a rat kidney homogenate preparation. 
We are currently studying the thermolysin medi- 
ated degradation of [Mpr7,Ala20,D-Arg27]- 
rANF7_z7-NH2 in an effort to identify the 
physiologically relevant cleavage sites. 
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